Galera Therapeutics Inc (GRTX) ニュース

Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

MALVERN, Pa., April 26, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Current Report Filing (8-k)

false 0001563577 0001563577 2023-03-10 2023-03-10 0001563577 dei:FormerAddressMember 2023-03-10 2023-03-10     UNITED STATES...

Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology

MALVERN, Pa., March 10, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage...

Annual Report to Security Holders (ars)

Annual Report (10-k)

00015635775--12-31FYfalsethree years0001563577us-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsM...

Current Report Filing (8-k)

false 0001563577 0001563577 2023-03-08 2023-03-08     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  ...

Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates

Avasopasem NDA granted FDA priority review for radiotherapy-induced severe oral mucositis (SOM); PDUFA target...

Statement of Ownership (sc 13g)

  SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549   SCHEDULE 13G (Rule 13d-102)   INFORMATION TO BE...

Current Report Filing (8-k)

false 0001563577 0001563577 2023-02-15 2023-02-15     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  ...

Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)

Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-251061 PROSPECTUS SUPPLEMEN...

Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants

MALVERN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage...

Current Report Filing (8-k)

false 0001563577 0001563577 2023-02-15 2023-02-15     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  ...